Compare LyondellBasell Industries NV (LYB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs State Street SPDR S&P Biotech ETF — how do they compare? LyondellBasell Industries NV trades at $62.99 (market cap $20.67B), while State Street SPDR S&P Biotech ETF trades at $158.94. The key difference: LyondellBasell Industries NV pays a 6.44% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, LyondellBasell Industries NV nearer its low. Which is the better fit depends on your goals.
| LYB | XBI | |
|---|---|---|
Market Cap | $20.67B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $82.38 | $164.28 |
52-Week Low | $42.28 | $86.92 |
Enterprise Value | $32.26B | — |
Dividend Yield | 6.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYB trades at $62.97, up 0.51% today, with a bullish technical signal from moving averages and a consensus analyst price target of $70.56. Recent Q2 2026 earnings of $4.30 per share beat estimates, driven by improved margins from supply disruptions and cost cuts. However, 2025 fundamentals show declining revenue to $30.15B and a net loss of $745M, though cash flow remains positive. The stock is near its 52-week high of $83.94, reflecting optimism around operational improvements.
Outlook: Near-term upside exists from earnings momentum and favorable supply dynamics, but risks include volatile chemical margins and high debt. Analyst sentiment is mixed with 46% buy ratings, suggesting cautious optimism amid cyclical challenges.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
